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Abstract
Twenty-ﬁve extended-spectrum b-lactamase (ESBL)-producing
Escherichia coli clinical isolates from Rio de Janeiro, Brazil were
characterized by isoelectric focusing, PCR and sequencing of
blaESBL genes, plasmid-mediated quinolone resistance determi-
nants, phylogenetic groups, replicon typing, pulsed-ﬁeld electro-
phoresis, and multilocus sequencing typing. Twenty-three (92%)
ESBL-producing E. coli isolates were positive for blaCTX-M genes,
aac(6¢)-Ib-cr, and qnrB. Genetic relatedness of ESBL producers
clustered seven (28%) CTX-M-15-producing isolates as sequence
type (ST)410, clonal complex (CC) 23, and two (8%) as clone
O25-ST131. Our results illustrate the predominance of phylo-
group A (52%), ST410 (CC 23) and CTX-M-15 among ESBL-
producing E. coli isolates from hospitals in Rio de Janeiro.
Keywords: Brazil, CTX-M-15, Escherichia coli, phylogroup A,
ST410
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Extended-spectrum b-lactamase (ESBL) production is a com-
mon mechanism of antimicrobial resistance among Gram-
negative bacteria. ESBL-producing Escherichia coli strains
cause several types of infection, including urinary tract infec-
tions, and are associated with increased patient morbidity
and mortality [1]. CTX-M-type enzymes are the most preva-
lent ESBLs detected on a worldwide basis, mainly in E. coli.
CTX-M b-lactamases include more than 80 different
enzymes, clustered into ﬁve groups: CTX-M-1, CTX-M-2,
CTX-M-8, CTX-M-9, and CTX-M-25 [2]. Recently, a particu-
lar clone of CTX-M-15-producing E. coli identiﬁed as
sequence type (ST)131 by multilocus sequence typing (MLST)
has been identiﬁed from several countries [3]. The ST131
clone is characterized by belonging to the highly virulent phy-
logenetic type B2, serotype O25:H4, and harbouring multi-
drug-resistant IncFII plasmids, and appears to be responsible
for a large proportion of the international epidemic of CTX-
M-producing E. coli [4]. In Brazil, ESBL-producing Enterobacte-
riaceae have been increasingly recovered from both hospitals
[5–7] and community settings [8, 9] as important causes of
bacteraemia and urinary tract infections.
The present study was undertaken to characterize ESBL-
producing E. coli isolates collected from public hospitals in
Rio de Janeiro. Twenty-ﬁve non-duplicate b-lactam-resistant
E. coli isolates were retained for study from both inpatients
(n = 16) and outpatients (n = 9) in hospitals located in the
Rio de Janeiro metropolitan area, Brazil, from February 2008
to June 2009. Isolates were recovered from blood (n = 8),
urine (n = 8), rectal swabs (n = 6), ascitic ﬂuid (n = 2) and
wound (n = 1) cultures. ESBL production was detected
according to the 2009 CLSI guidelines, i.e. screening with cef-
triaxone and ceftazidime at 1 mg/L, respectively, and conﬁrm-
ing with ceftazidime, ceftazidime/clavulanate, cefotaxime and
cefotaxime/clavulanate disks [10]. Antimicrobial susceptibility
testing was determined with the VITEK 2 instrument (Vitek
AMS; bioMerieux Vitek Systems, Hazelwood, MO, USA). The
MICs of the following drugs were determined with a custom-
made Gram-negative card (AST-N121): piperacillin–tazobac-
tam (concentrations (mg/L), 4/4, 16/4, 32/4 and 64/4), ertape-
nem (concentrations (m/L), 0.5, 1 and 4), meropenem
(concentrations (mg/L), 0.5, 4 and 16), ciproﬂoxacin (concen-
trations (mg/L), 0.5, 2 and 4), gentamicin (concentrations
(mg/L), 4, 16 and 32), trimethoprim–sulphamethoxazole (con-
centrations (mg/L), 1/19, 4/76 and 16/304), amoxycillin–clavul-
anic acid (concentrations (mg/L), 4/2, 16/8 and 32/16),
nitrofurantoin (concentrations (mg/L), 16, 32 and 64), amika-
cin (concentrations (mg/L), 8, 16 and 64), tobramycin (con-
centrations (mg/L), 8, 16 and 64), and cefoxitin
(concentrations (mg/L), 8, 16 and 32). Throughout this study,
results were interpreted according to CLSI criteria [10]. Of
the 25 isolates, 24 (96%) were non-susceptible (i.e. intermedi-
ate or resistant) to trimethoprim–sulphamethoxazole, 23
(92%) to ciproﬂoxacin and amoxycillin–clavulanic acid, 20
(80%) to tobramycin, 15 (60%) to gentamicin, seven (28%) to
piperacillin–tazobactam and cefoxitin, six (24%) to amikacin,
and three (12%) to nitrofurantoin. The MICs of ceftriaxone
ranged from 8 to >32 mg/mL, those of ceftazidime from 1 to
>32 mg/L, and and those of cefepime from 2 to >32 mg/L.
ESBLs were identiﬁed as previously reported [11].
Twenty-three isolates (92%) were positive for blaCTX-M
genes: 16 produced CTX-M-15, three produced CTX-M-8,
two produced CTX-M-3, and two produced CTX-M-2,
whereas the remaining two isolates produced SHV-2. Some
of the CTX-M-producing isolates also produced TEM-1 and
OXA-1 (i.e. those with CTX-M-3 and CTX-M-15) b-lacta-
mases (Table 1).
Ampliﬁcation of qnrA, qnrB and qnrS was undertaken in all
CTX-M-positive isolates by multiplex PCR [12]. The aac(6¢)-
Ib-cr and qepA genes were ampliﬁed in a separate PCR
[12,13]. Eleven (44%) of the ESBL-producing E. coli isolates
were positive for aac(6¢)-Ib-cr, four (16%) were positive for
both qnrB and aac(6¢)-Ib-cr, and one was positivefor qnrB
(Table 1).
The clonal relationship between CTX-M producers was
determined by pulsed-ﬁeld gel electrophoresis (PFGE) and
MLST. All ESBL-producing isolates were screened for clone
O25-ST131 with a PCR for the pabB allele [14]. Phylogenetic
analyses were performed with the algorithm eBUSRT V3
[15]. Overall, 16 isolates were considered to be non-related
by PFGE, indicating that ESBL-producing E. coli isolates con-
stituted a relatively diverse population. Only one PFGE clus-
ter (comprising seven isolates) was clearly identiﬁed among
the 23 typeable E. coli isolates (Fig. 1). Nevertheless, isolates
of this clonal group shared <85% similarity by PFGE, were
identiﬁed as ST410, and belonged to clonal complex (CC)23
according to MLST (Fig. 2). Two isolates were conﬁrmed to
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be ST131 with PCR for the pabB allele and MLST, but they
did not cluster together by PFGE.
The ESBL-producing E. coli isolates were assigned to phy-
logenetic groups A (n = 13), B1 (n = 5), B2 (n = 4) and D
(n = 3) by multiplex PCR [16]. Phylogroup B2 comprised the
two ST131 isolates and also two non-ST131 CTX-M-15-pro-
ducing isolates. All but one ST410 isolate belonged to phylo-
genetic group A.
Plasmid sizes were determined with the use of previously
described protocols and conditions [11], and assigned to
plasmid families by PCR-based replicon typing [17]. Conjuga-
tion experiments were performed by mating-out assays with
a selection agar containing ceftriaxone 1 mg/L and E. coli
C600N as recipient. The plasmid sizes in the CTX-M pro-
ducers ranged from 80 to 135 kb, and belonged to the nar-
row host range incompatibility group IncFII, and the FIA and
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FIG. 1. Pulsed-ﬁeld gel electrophoresis (PFGE) of XbaI-digested DNA of 23 extended-spectrum b-lactamase (ESBL)-producing Escherichia coli iso-
lates from Rio de Janeiro.
TABLE 1 Characteristics of extended-spectrum b-lactamase-producing Escherichia coli isolates in Rio de Janeiro
Isolate no. Specimen Antimicrobial non-susceptibilitya PMQR b-Lactamases
Phylogenetic
group
BRA 3912 Blood TZP, CIP, SXT, AMC, AMK, TOB aac(6¢)-lb-cr CTX-M-15 A
BRA 3995 Blood CIP, NIT – CTX-M-8 B1
BRA 4074 Urine CIP, SXT, AMC – CTX-M-2 A
BRA 4118 Blood TZP, CIP, GEN, SXT, AMC, AMK, TOB, FOX aac(6¢)-lb-cr/qnrB CTX-M-15 B2
BRA 4134 Ascitic ﬂuid SXT, AMC, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 A
BRA 4141 Urine CIP, SXT, AMC, NIT, TOB, FOX aac(6¢)-lb-cr CTX-M-15 A
BRA 4147 Urine SXT, AMC – CTX-M-2 B1
BRA 4155 Blood CIP, GEN, SXT, AMC, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 B2
BRA 4168 Urine CIP, GEN, SXT, AMC, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 A
BRA 4225 Blood CIP, SXT, AMC, AMK, TOB aac(6¢)-lb-cr TEM-1, CTX-M-15 A
BRA 4318 Ascitic ﬂuid TZP, CIP, GEN, SXT, AMC, AMK, TOB aac(6¢)-lb-cr/qnrB TEM-1, OXA-1, CTX-M-15 B1
BRA 4334 Urine TZP, CIP, GEN, SXT, AMC, TOB – TEM-1, OXA-1, CTX-M-15 B2
BRA 4374 Blood CIP, GEN, SXT, TOB – SHV-2 D
BRA 4417 Urine TZP, CIP, GEN, SXT, AMC, TOB, FOX aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-3 B2
BRA 4422 Wound CIP, SXT, AMC, FOX – OXA-1, CTX-M-15 A
BRA 4631 Blood CIP, GEN, SXT, AMC, TOB, FOX aac(6¢)-lb-cr/qnrB TEM-1, CTX-M-15 B1
BRA 4718 Urine CIP, GEN, SXT, AMC, TOB – SHV-2 A
BRA 4771 Blood CIP, GEN, SXT, AMC, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 A
BRA 4839 Urine CIP, GEN, SXT, AMC, TOB, FOX – TEM-1, OXA-1, CTX-M-3 D
BRA 4842 Rectal swab CIP, SXT, AMC, TOB aac(6¢)-lb CTX-M-8 B1
BRA 4857 Rectal swab SXT, AMC qnrB CTX-M-8 A
BRA 4861 Rectal swab CIP, GEN, SXT, AMC, NIT, AMK, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 A
BRA 4991 Rectal swab CIP, GEN, SXT, AMC, TOB aac(6¢)-lb-cr TEM-1, OXA-1, CTX-M-15 A
BRA 4993 Rectal swab CIP, GEN, SXT, AMC, TOB aac(6¢)-lb-cr OXA-1, CTX-M-15 A
BRA 4998 Rectal swab TZP, CIP, GEN, SXT, AMC, AMK, TOB, FOX aac(6¢)-lb-cr/qnrB TEM-1, OXA-1, CTX-M-15 D
AMC, amoxycillin–clavulanic acid; AMK, amikacin; CIP, ciproﬂoxacin; FOX, cefoxitin; GEN, gentamicin; NIT, nitrofurantoin; PMQR, plasmid-mediated quinolone resistance
determinant; SXT, trimethoprim–sulphamethoxazole; TOB, tobramycin; TZP, piperacillin/tazobactam..
aAntimicrobial non-susceptibility (i.e. resistant or intermediate).
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FIB (18 isolates), P and B/O (one isolate), FIB (three isolates)
and repF (one isolate) replicons were detected.
In the present study, CTX-M-15 enzymes were the most
common ESBLs detected; the isolates producing these were
multiresistant, and co-produced TEM-1 and OXA-1 b-lacta-
mases; the majority were positive for aac(6¢)-lb-cr, and
belonged to phylogenetic group A. PFGE showed one domi-
nant clone and MLST analysis identiﬁed it as ST410 (CC23),
which belonged to phylogenetic group A. This was the ﬁrst
detection of ST410 CC23 in Brazil, where recent MLST stud-
ies showed high genetic variability among E. coli isolates
[18,19]. The detection of ST410/phylogroup A has so far
been described in one CTX-M-14-producing E. coli isolate
from Spain [20].
Our study also detected aac(6¢)-Ib-cr among isolates from
Brazil, highlighting the prevalence of this plasmid-mediated
quinolone resistance gene, and indicates that there is wide-
spread dissemination of aac(6¢)-Ib-cr, particularly associated
with CTX-M-producing isolates.
In conclusion, this study constitutes the ﬁrst report of
ST410 (CC23) isolates producing CTX-M-15 with the associ-
ation of aac(6¢)-Ib-cr as a plasmid-mediated quinolone resis-
tance gene in Brazil.
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Abstract
Because of limitations in infrastructure, the aetiology of infec-
tions caused by anaerobic bacteria is seldom determined in clini-
cal laboratories of developing countries. This study reports on
the identiﬁcation of 1010 anaerobic bacterial isolates collected
between 1999 and 2008 in a major Costa Rican hospital with
the use of two commercial phenotypic systems (RapID 32A
and API 20A). Approximately 60% of the isolates were
Gram-positive and, among the 35 species of Gram-positive bac-
teria found, the genera Clostridium, Propionibacterium and Eggerth-
ella, and anaerobic cocci predominated. Twenty eight species
were found among 395 isolates of Gram-negative bacteria. Spe-
cies of Bacteroides were very frequent, followed by species of
Prevotella, Veillonella, Fusobacterium and Porphyromonas.
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Numerous species of anaerobic bacteria proliferate in the
surfaces and cavities that make up the human body. This
anaerobic microbiota is innocuous under usual conditions;
however, it can cause pathology in the head and neck area,
the thorax, the abdomen, the skin and soft tissues or the
urogenital tract when certain predisposing conditions are
present, such as compromised integrity of the skin or muco-
sae, necrosis resulting from ischaemic processes or the
formation of abscesses [1].
The majority of clinical laboratories in Costa Rica and in
other developing countries lack the infrastructure and expe-
rience required to isolate and identify anaerobic bacteria [2].
Such an absence of knowledge on the aetiology of infections
caused by anaerobic bacteria has serious epidemiological
repercussions and forces local clinicians to prescribe antibi-
otic therapy empirically when treating these infections.
Moreover, clinicians often follow the trends and recommen-
dations for developed countries, which may not always apply
to the epidemiological characteristics of developing societies.
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